These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 3549989

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.
    Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M.
    J Nucl Med; 1987 Mar; 28(3):281-7. PubMed ID: 3102699
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma.
    Dillman RO, Beauregard J, Shawler DL, Halpern SE, Markman M, Ryan KP, Baird SM, Clutter M.
    J Biol Response Mod; 1986 Oct; 5(5):394-410. PubMed ID: 3490543
    [Abstract] [Full Text] [Related]

  • 7. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA.
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [Abstract] [Full Text] [Related]

  • 8. Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma.
    Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA, Reynolds JC, Foon KA, Smarte NC, Ghosh B, Fejka RM, Larson SM.
    Cancer Res; 1987 Nov 15; 47(22):6093-9. PubMed ID: 3499222
    [Abstract] [Full Text] [Related]

  • 9. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM.
    Cancer Res; 1996 Apr 15; 56(8):1805-16. PubMed ID: 8620497
    [Abstract] [Full Text] [Related]

  • 10. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug 15; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 11. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF.
    J Clin Oncol; 1994 Aug 15; 12(8):1561-71. PubMed ID: 8040668
    [Abstract] [Full Text] [Related]

  • 12. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody.
    Carrasquillo JA, Bunn PA, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Su MH, Gazdar AF, Mulshine JL, Oldham RK.
    N Engl J Med; 1986 Sep 11; 315(11):673-80. PubMed ID: 3489185
    [Abstract] [Full Text] [Related]

  • 13. Tissue distribution and serum kinetics of T101 monoclonal antibody during passive anti-cancer therapy.
    Shawler DL, Beauregard J, Halpern SE, Baird SM, Dillman RO.
    Clin Immunol Immunopathol; 1986 Oct 11; 41(1):43-54. PubMed ID: 3488861
    [Abstract] [Full Text] [Related]

  • 14. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
    DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O'Grady LF, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S.
    Cancer Biother Radiopharm; 1998 Aug 11; 13(4):239-54. PubMed ID: 10850360
    [Abstract] [Full Text] [Related]

  • 15. Milestones in the development of Lym-1 therapy.
    DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ.
    Hybridoma; 1999 Feb 11; 18(1):1-11. PubMed ID: 10211782
    [Abstract] [Full Text] [Related]

  • 16. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
    Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO.
    J Clin Oncol; 1991 Apr 11; 9(4):548-64. PubMed ID: 2066752
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP.
    J Clin Oncol; 1992 Nov 11; 10(11):1696-711. PubMed ID: 1403053
    [Abstract] [Full Text] [Related]

  • 19. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B.
    N Engl J Med; 1993 Oct 21; 329(17):1219-24. PubMed ID: 7692295
    [Abstract] [Full Text] [Related]

  • 20. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL, DeNardo SJ, Macey DJ, Shen S, Kroger LA.
    Cancer; 1994 Feb 01; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.